Fairvalue-Calculator Fairvalue-Calculator
EN DE

Protect Pharmaceutical Corporation (PRTT) Fair Value & Analysis

Industrials · US · Market cap $6.3M

Price$0.0600
Fair Value$0.1114
Upside+85.7%
Quality95/100
Evidence: Low Range $0.0874 – $0.1351

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Protect Pharmaceutical Corporation (PRTT) currently trades at $0.0600, while our model-based Fair Value estimate is $0.1114 — implying the stock looks roughly 85.7% undervalued today. We read business quality at 95/100 (high quality), in the Industrials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Protect Pharmaceutical Corporation primarily focuses on crop farming and agricultural businesses. It acquires the Can Noguera property located in Selva Girona region in Spain. Its property consists of 60 hectares of arable land, 390 hectares of forests, 6 mineral and freshwater wells, and 3000 square meters of built properties. The company was formerly known as Pro-Tect, Inc. and changed its name to Protect Pharmaceutical Corporation in March 2010. Protect Pharmaceutical Corporation was founded in 1987 and is based in Las Vegas, Nevada.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Protect Pharmaceutical Corporation (PRTT) undervalued?
As of Jun 26, 2026, our model estimates a fair value of $0.1114 versus a price of $0.0600 — about +86% (undervalued). Model-based estimate, not financial advice.
What is the fair value of PRTT?
Our 21-model fair value for Protect Pharmaceutical Corporation is $0.1114 (as of Jun 26, 2026), built from audited fundamentals. The current price is $0.0600.
What is the quality score of PRTT?
Protect Pharmaceutical Corporation has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.